Art. -Nr.: HY-17356

Fenofibrate

35 Cited Publications

Kundenbewertung

Based on 35 publication(s) in Google Scholar

Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.97%
CAS. Nr.: 49562-28-9
Formel: C₂₀H₂₁ClO₄
Molecular Weight:360.83

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Fenofibrate Chemical Structure

CAS. Nr.: 49562-28-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (35)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

CYP2C19

0.2 μM (IC₅₀)

CYP2B6

0.7 μM (IC₅₀)

CYP2C9

9.7 μM (IC₅₀)

CYP2C8

4.8 μM (IC₅₀)

CYP3A4

142.1 μM (IC₅₀)

PPARα

30 μM (IC₅₀)

Alle PPAR Isoform-spezifische Produkte anzeigen :

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	15.9 μM Compound: 24	Antiproliferative activity against human A549 cells after 120 hrs by MTT assay Antiproliferative activity against human A549 cells after 120 hrs by MTT assay	[PMID: 16680159]
CHO-K1	EC₅₀	49 μM Compound: Fenofibrate	In vitro effective concentration for agonist activity on rat Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CHO-K1 cells In vitro effective concentration for agonist activity on rat Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CHO-K1 cells	[PMID: 12904063]
CHO-K1	EC₅₀	50 μM Compound: Fenofibrate	In vitro effective concentration for agonist activity on dog Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CHO-K1 cells In vitro effective concentration for agonist activity on dog Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CHO-K1 cells	[PMID: 12904063]
COS-1	EC₅₀	>5000 nM Compound: Fenofibrate	Agonist activity at human PPARgamma receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay Agonist activity at human PPARgamma receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay	[PMID: 19530681]
COS-1	EC₅₀	2 μM Compound: Fenofibrate	Agonist activity at human PPARalpha receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay Agonist activity at human PPARalpha receptor expressed in african green monkey COS1 cells co-transfected with fused yeast Gal4-DBD by transactivation assay	[PMID: 19530681]
HEK293	EC₅₀	33.51 μM Compound: Fenofibrate	Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HepG2	EC₅₀	50 μM Compound: 1	Transactivation of human GAL4-fused PPARalpha LBD expressed in human HepG2 cells after 24 hrs by renilla luciferase reporter gene assay Transactivation of human GAL4-fused PPARalpha LBD expressed in human HepG2 cells after 24 hrs by renilla luciferase reporter gene assay	[PMID: 31320147]
LoVo	IC₅₀	13.2 μM Compound: 24	Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay	[PMID: 16680159]
MIA PaCa-2	IC₅₀	8.4 μM Compound: 24	Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay	[PMID: 16680159]
PC-3	IC₅₀	18 μM Compound: 24	Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay	[PMID: 16680159]
U-87MG ATCC	IC₅₀	74.5 μM Compound: 24	Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay	[PMID: 16680159]

In Vitro

Fenofibrate is a relatively potent inhibitor of CYP2B6 (IC₅₀=0.7±0.2 μM) and CYP2C19 (IC₅₀=0.2±0.1 μM). Fenofibrate is also a moderate inhibitor of CYP2C8 (IC₅₀=4.8±1.7 μM) and CYP2C9 (IC₅₀=9.7 μM)^[1]. Fenofibrate binds to and inhibits cytochrome P450 epoxygenase (CYP)2C with higher affinity than to PPARα. Fenofibrate is a well-known PPARα agonist, but an in vitro assessment of 209 frequently prescribed drugs and related xenobiotics suggests that Fenofibrate is also a potent inhibitor of cytochrome P450 epoxygenase (CYP)2C. The affinity of Fenofibrate to CYP2C is >10 times higher (EC₅₀=2.39±0.4 μM) than to PPARα (EC₅₀=30 μM). Fenofibrate at a low dose inhibits CYP2C8 activity without PPARα activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Daily intake of Fenofibrate at this low dose (10 μg/g/day) inhibits retinal and choroidal neovascularization induced by CYP2C8 overexpression by 29% (P=0.021) and 36% (P=1.2×10⁹) respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 49562-28-9
Appearance Solid
Molecular Weight 360.83
Formel C₂₀H₂₁ClO₄
Color White to off-white
SMILES

CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(OC(C)C)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (35)

All Bio/Physico-chemical AssayWBHistological Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell Metab

The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. [Abstract]

2025 Oct 22:S1550-4131(25)00396-1. PMID: 41130202

Fenofibrate purchased from MedChemExpress. Usage Cited in: Cell Metab. 2025 Oct 22:S1550-4131(25)00396-1. [Abstract]

Acyl-CoA relative levels in mouse primary hepatocytes after 4 or 24 h treatment of 326E (100 μM) and Fenofibrate (100 μM).

Fenofibrate purchased from MedChemExpress. Usage Cited in: Cell Metab. 2025 Oct 22:S1550-4131(25)00396-1. [Abstract]

After 7-day oral treatment with Fenofibrate (40 mg/kg, calculated based on clinical dose), SB204990 (150 mg/kg), SB204990 (150 mg/kg) plus fenofibrate(40 mg/kg), BA (30 mg/kg), or 326E (30 mg/kg) in MASH mice (induced by Gan diet or CDAA-HFD), hepatic DNL was assessed by 14C-acetate tracing.
Mol Cell

CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. [Abstract]

2023 Dec 7;83(23):4370-4385.e9. PMID: 38016475
Hepatology

Hepatic PPARα function is controlled by polyubiquitination and proteasome-mediated degradation through the coordinated actions of PAQR3 and HUWE1. [Abstract]

2018 Jul;68(1):289-303. PMID: 29331071

Fenofibrate purchased from MedChemExpress. Usage Cited in: Hepatology. 2018 Jul;68(1):289-303. [Abstract]

PAQR3 modulates fatty acid oxidation in hepatocytes. The cells in panel A were treated with WY14643 (30 lM) or Fenofibrate (50 lM) for 24 hours, followed by measurement of the fatty acid oxidation rate.
Adv Sci (Weinh)

Asprosin-FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development. [Abstract]

2025 Apr 15:e2415846. PMID: 40231957

Fenofibrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 15:e2415846. [Abstract]

After treatment with asprosin overexpression plasmid for 24 h, primary hepatocytes were treated with Fenofibrate (100 μM) for 24 h. The protein level of PPARα was analyzed by Western blot.

Fenofibrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr 15:e2415846. [Abstract]

C57BL/6 J mice were fed on HFCDAA and treated with the indicated AAVs. After C57BL/6 J mice were fed on HFCDAA for 4 weeks, mice were injected with vehicle or Fenofibrate (100 mg/kg) for 4 weeks.
Carbohydr Polym

Reactive oxygen species-sensitive fenofibrate-loaded dextran nanoparticles in alleviation of osteoarthritis. [Abstract]

2025 Jan 1:347:122768. PMID: 39486995
Cardiovasc Diabetol

Growth differentiation factor 11 regulates high glucose-induced cardiomyocyte pyroptosis and diabetic cardiomyopathy by inhibiting inflammasome activation. [Abstract]

2024 May 7;23(1):160. PMID: 38715043
Int J Biol Macromol

Carnosine-modified gelatin-hyaluronic acid hydrogel comprising fenofibrate-loaded nanoparticles targeting chondrocyte ferroptosis and macrophage polarization for synergistic osteoarthritis therapy. [Abstract]

2026 Apr:354:151281. PMID: 41812949
Acta Pharmacol Sin

A novel mouse model of familial combined hyperlipidemia and atherosclerosis. [Abstract]

2024 Jun;45(6):1316-1320. PMID: 38459255
Acta Pharmacol Sin

PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway. [Abstract]

2022 Jan;43(1):167-176. PMID: 33772142
Phytomedicine

Geniposidic acid alleviated metabolic dysfunction-associated steatotic liver disease by exciting SIRT6 signaling. [Abstract]

2025 Oct:146:157140. PMID: 40782762
Phytomedicine

An integrated network pharmacology and cell metabolomics approach to reveal the role of rhein, a novel PPARα agonist, against renal fibrosis by activating the PPARα-CPT1A axis. [Abstract]

2022 May 6;102:154147. PMID: 35567992
Cell Rep

DUSP14 suppresses ferroptosis and promotes tumor progression of triple-negative breast cancer. [Abstract]

2025 Sep 30;44(10):116365. PMID: 41032417
Cell Rep

Caveolin-1/PPARα axis suppresses T follicular helper cell response in primary Sjögren disease. [Abstract]

2025 Aug 12;44(8):116156. PMID: 40802512
Int J Mol Med

Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend. [Abstract]

2026 Apr;57(4):102. PMID: 41789618
Biochem Pharmacol

Inhibition of RAGE-mediated inflammatory signaling by Boletus edulis Bull: Fr. Polysaccharide alleviates lipotoxicity-induced metabolic dysfunction. [Abstract]

2025 Oct 18;243(Pt 1):117439. PMID: 41115475
Int J Mol Sci

Novel Aurone Derivative Ameliorates MASH Lipid Metabolism via the AMPK-ACC-PPARα Axis. [Abstract]

2025 Nov 17;26(22):11099. PMID: 41303582
Pharmaceuticals (Basel)

ZLN005 Alleviates In Vivo and In Vitro Renal Fibrosis via PGC-1α-Mediated Mitochondrial Homeostasis. [Abstract]

2022 Mar 31;15(4):434. PMID: 35455432
Bioorg Chem

Euphorbia factor L3 ameliorates hepatic steatosis by activating LKB1-AMPK signaling pathway-regulated lipid metabolism. [Abstract]

2026 Sep 5:179:110008. PMID: 42176359
Eur J Pharmacol

Ginsenoside Rb1 promotes the activation of PPARα pathway via inhibiting FADD to ameliorate heart failure. [Abstract]

2023 May 15:947:175676. PMID: 37001580
Front Cell Dev Biol

Enhancing Fatty Acid Catabolism of Macrophages Within Aberrant Breast Cancer Tumor Microenvironment Can Re-establish Antitumor Function. [Abstract]

2021 Apr 15;9:665869. PMID: 33937269
Mol Nutr Food Res

Sesaminol Ameliorates Metabolic and Alcohol-Related Liver Injury by Activating the PPARα/Slc27a5 Axis-Driven Hepatic Fatty Acid β-Oxidation. [Abstract]

2026 May;70(10):e70506. PMID: 42170787
Exp Neurol

Triiodothyronine ameliorates S-ketamine-induced hypomyelination via the PPARα pathway in neonatal rat. [Abstract]

2025 Apr 15:389:115260. PMID: 40246008
Biochim Biophys Acta Mol Basis Dis

Pharmacological targeting of AMPK to restore glucose and fatty acid metabolism homeostasis attenuates transplanted kidney fibrosis. [Abstract]

2024 Sep 13:167510. PMID: 39278511
Cell Signal

Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice. [Abstract]

2026 Mar:139:112357. PMID: 41506518
Heliyon

Shenmai injection improves lipid metabolism in post-myocardial infarction heart failure based on network pharmacology and experimental validation. [Abstract]

2024 Oct 5;10(21):e38648. PMID: 39524885
Viruses

Paraoxonase-1 Facilitates PRRSV Replication by Interacting with Viral Nonstructural Protein-9 and Inhibiting Type I Interferon Pathway. [Abstract]

2022 May 31;14(6):1203. PMID: 35746674
Nanotoxicology

Graphene oxide nanoparticles induce hepatic dysfunction through the regulation of innate immune signaling in zebrafish ( Danio rerio). [Abstract]

2020 Jun;14(5):667-682. PMID: 32141807
Hum Exp Toxicol

Effect of fenofibrate on proliferation of SMMC-7721 cells via regulating cell cycle. [Abstract]

2021 Jul;40(7):1208-1221. PMID: 33538198
Mol Pharmacol

Fenofibrate promotes erucic acid metabolism by peroxisome enzyme EHHADH activation alleviating high-fat diet-induced steatotic liver disease. [Abstract]

2025 May 16;107(7):100047. PMID: 40516250
Biomed Chromatogr

Study on the Effect and Mechanism of Lomatogonium rotatum (L.) Fries ex Nym Extract on NAFLD Through Metabolomics. [Abstract]

2026;40(2):e70323. PMID: 41532219
SSRN

2025 Sep 22.
Seoul National University

2025.
SSRN

2025 Aug 12.
Environ Sci Pollut Res Int

Lead exposure induced lipid metabolism disorders by regulating the lipophagy process in microglia. [Abstract]

2023 Dec;30(60):125991-126008. PMID: 38008839
Evid Based Complement Alternat Med

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPAR α Signaling Pathway. [Abstract]

2022 Jan 7:2022:1124901. PMID: 35035496

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (277.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7714 mL

13.8569 mL

27.7139 mL

5 mM

0.5543 mL

2.7714 mL

5.5428 mL

10 mM

0.2771 mL

1.3857 mL

2.7714 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.93 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 33.33 mg/mL (92.37 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

The half-maximal inhibitory concentrations (IC₅₀s) of Fenofibrate, statins (atorvastatin, lovastatin, pravastatin, simvastatin and simvastatin acid, the active form of simvastatin) and glipizide for recombinant human CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are determined using fluorometric CYP450 inhibition assays. Briefly, the drugs are dissolved in methanol or acetonitrile. In 96 well assay plates, the drugs are diluted to a series of concentrations in a solution containing cofactors including NADP⁺ (final concentration 1.3 mM), MgCl₂ (final concentration 3.3 m M), glucose-6-phosphate (G6P, final concentration 3.3 mM) and glucose 6-phosphate dehydrogenase (final concentration 0.4 U/mL). The mixture is pre-incubated at 37°C for 10 min. The enzymes and fluorogenic substrates are diluted to desired concentrations in sodium phosphate reaction buffer (pH 7.4, final concentration 200 mM) and mixed. Reactions are initiated with addition of the enzyme and substrate mixture to the cofactor and drug mixture. The final reaction volume of all assays is 200 μL. After incubating at 37°C for a pre-specified period of time (15 to 45 min), the reactions are stopped with addition of 75 μL quenching solution (0.5 M Tris base or 2N NaOH). Fluorescence is determined using a BioTek Synergy 2 fluorescence reader. Each of the drugs is tested at eight concentrations in duplicate. To estimate IC₅₀s, percent of inhibition is calculated using net fluorescence that is corrected for the background. The values of percent of inhibition are then fitted to a three or four parameter log-logistic model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
The mouse oxygen-induced retinopathy (OIR) model is used. Briefly to induce retinal neovascularization, mouse pups and their nursing mother are exposed to 75±3% oxygen from P7 to P12. For the higher dose Fenofibrate (F6020) treatment (100 mg/kg/day). Fenofibrate is dissolved in corn oil to make 100mg/mL solution and pure corn oil is used as vehicle control. For the lower dose treatment (10 mg/kg/day), Fenofibrate is dissolved in 10% DMSO, D2650 to make a 10 mg/mL solution and 10% DMSO is used as vehicle control. After return to room air, mice are orally gavaged with Fenofibrate (100 or 10 mg/kg) or vehicle control daily from P12 to P16. At P17, eyes are enucleated immediately after euthanasia and fixed in 4% paraformaldehyde in PBS for 1 h at room temperature. Retinas are then dissected and stained overnight with Alexa Fluor 594 conjugated isolectin GS-IB4 (10 μg/mL) at room temperature. After washing with PBS, retinas are mounted onto microscope slides with photoreceptor side down and embedded in SlowFade antifade mounting medium. Retinal images are taken using a fluorescence microscope with image software. Retinal neovascularization is analyzed.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78(3):639-48. [Content Brief]

[2]. Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964(16)30448-0. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7714 mL	13.8569 mL	27.7139 mL	69.2847 mL
	5 mM	0.5543 mL	2.7714 mL	5.5428 mL	13.8569 mL
	10 mM	0.2771 mL	1.3857 mL	2.7714 mL	6.9285 mL
	15 mM	0.1848 mL	0.9238 mL	1.8476 mL	4.6190 mL
	20 mM	0.1386 mL	0.6928 mL	1.3857 mL	3.4642 mL
	25 mM	0.1109 mL	0.5543 mL	1.1086 mL	2.7714 mL
	30 mM	0.0924 mL	0.4619 mL	0.9238 mL	2.3095 mL
	40 mM	0.0693 mL	0.3464 mL	0.6928 mL	1.7321 mL
	50 mM	0.0554 mL	0.2771 mL	0.5543 mL	1.3857 mL
	60 mM	0.0462 mL	0.2309 mL	0.4619 mL	1.1547 mL
	80 mM	0.0346 mL	0.1732 mL	0.3464 mL	0.8661 mL
	100 mM	0.0277 mL	0.1386 mL	0.2771 mL	0.6928 mL

Keywords

Fenofibrate

35 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Fenofibrate

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Antidepressant Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Anti-Aging Natural Product Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Chinese Baijiu Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Fenofibrate

Alle PPAR Isoform-spezifische Produkte anzeigen

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (35)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fenofibrate Related Classifications

HY-17356 Related Classifications